ENO2 and pancreatic neuroendocrine tumor: reported that early CgA and NSE response (≥ 30% decrease of CgA or NSE from baseline or normalization at week 4) were predictors for longer PFS and OS in advanced pancreatic NET patients receiving everolimus treatment (RADIANT-1 study).